Colidiaryl

Quick links to important sections

Colidiaryl

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Colidiaryl

Colidiaryl: Defining Its Identity

Property Description
Active Ingredient Diosmectite (Aluminomagnesium Silicate)
Form Powder for Oral Suspension (Sachet)
Pharmacological Class Intestinal Adsorbent and Protectant
Common Use Symptomatic relief of acute diarrhea
Origin Natural Mineral (Clay)

Colidiaryl is an oral medicine that is classified as an intestinal adsorbent and protectant. It is a non-systemic agent, meaning it acts primarily within the gastrointestinal tract and is not absorbed significantly into the bloodstream, limiting potential systemic effects. This product is pharmacologically categorized within the class of Intestinal Adsorbents. Diosmectite is used as an effective option in managing symptoms of acute diarrhea.


What is Colidiaryl Made Of and How is it Sourced?

The active ingredient in Colidiaryl is Diosmectite, a natural aluminomagnesium silicate clay. This key component is mineral-based and of natural origin, distinguishing it from synthetic drug compounds. Colidiaryl is manufactured specifically as an oral powder in sachets and is often formulated with a mild, patient-friendly flavor to improve compliance.

The powder is designed to be mixed with water to create a suspension, ensuring the clay is dispersed and readily available to coat and protect the intestinal lining upon ingestion. This sachet format and flavor profile are key differentiating features that support its positioning as a readily accessible, over-the-counter (OTC) solution.


General Therapeutic Role of Colidiaryl

The general therapeutic purpose of Colidiaryl is the supportive management of acute digestive upset, primarily to aid in relieving the symptoms of diarrhea. Its function is rooted in its dual capacity to physically bind substances and reinforce the natural mucosal barrier.

This medicine is utilized for its role in supporting the management of short-term, acute diarrhea. Diosmectite acts to increase stool consistency and reduce stool output. In plain terms, the medicine helps stools become firmer and less frequent. This targeted, physical action makes it a valuable symptomatic relief agent.

What side effects are possible with Colidiaryl?

Official Adverse Reactions and Safety Profile

The safety profile of Colidiaryl is based on regulatory classifications of adverse reactions by frequency and physiological system, focusing primarily on its non-systemic action within the gastrointestinal tract.

Frequency Classification Associated Adverse Reactions
Common (1% to 10%) Constipation (may arise or be aggravated)
Uncommon (0.1% to 1%) Vomiting, Rash
Rare (0.01% to 0.1%) Urticaria (Hives)
Not Known Hypersensitivity, Angioedema, Pruritus

The officially documented adverse reactions are categorized under Gastrointestinal disorders (e.g., Constipation, Vomiting), Skin and subcutaneous tissue disorders (e.g., Rash, Urticaria), and Immune system disorders (e.g., Angioedema). Constipation is the most frequently reported adverse effect, which regulatory documents note is generally manageable through dose adjustment.

Population-Specific and Use-Related Constraints

Official regulatory documents include important safety constraints for specific populations and usage patterns. Due to precautionary safety measures related to the product's natural mineral origin, Colidiaryl is not recommended for use during pregnancy or lactation. Furthermore, its use is advised to be avoided in children under 2 years of age.

Because of the medicine's adsorbent property, official labeling notes that it has the potential to interfere with the absorption time and/or rate of any other substance taken orally. Additionally, prolonged or chronic use is generally advised to be avoided, and an overdose may lead to severe constipation or the formation of a bezoar.

Overdose and Emergency Response

The official regulatory profile for Colidiaryl overdose focuses on the consequences of its mechanical, non-systemic action within the gastrointestinal tract. As an intestinal adsorbent, the most notable documented manifestation of over-ingestion is an exaggeration of its intended effect, leading to severe gastrointestinal stasis. This is formally described in regulatory documents as severe constipation and carries the potential risk for serious mechanical complications such as bezoar formation or intestinal obstruction. No specific systemic life-threatening effects (e.g., cardiac or neurological events) are documented in official labeling, which is consistent with the drug’s minimal systemic absorption.

Overdose management is officially defined by regulatory authorities as symptomatic and supportive treatment, as label documentation explicitly confirms that no specific antidote is known. Due to the potential for serious mechanical complications, the regulator-mandated instruction is clear: any suspected overdose requires that users seek immediate medical attention. This action is specifically required if severe abdominal symptoms or persistent signs of obstruction are present, ensuring prompt supportive care as outlined by official documentation.

Therapeutic Uses of Colidiaryl

What Colidiaryl Treats: Main Uses and Benefits

Colidiaryl is commonly used in therapeutic areas involving certain distressing gastrointestinal symptoms. The medicine is utilized for symptomatic support in both acute diarrheal episodes and chronic functional diarrheal conditions.

This medicine is applied across domains where additional symptomatic support is needed, and may assist with managing the core symptom cluster of frequent, excessively loose, or watery stools, which often create noticeable physiological strain. It is commonly used during phases when symptoms become more noticeable and supportive relief is appropriate for acute episodes in pediatric and adult patients.

“The medicine may be used for symptomatic relief, which generally contributes to easing the overall symptom load,” especially when symptoms interfere with daily comfort. The medicine is considered relevant for use in conditions that include symptomatic management of acute episodes and supportive use in conditions like Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) in adults. This focused approach supports the patient during difficult episodes by easing distress.


Quick Fact: Relief for Disrupted Stool Form The medicine is commonly used to help with managing symptoms linked to abnormal stool fluidity.

Regulatory References

  1. NIH PubMed Central Review

Eligibility and Restrictions for Use

Who Can and Cannot Use Colidiaryl?

Eligibility for Colidiaryl (Diosmectite) is determined by regulatory-documented age restrictions, physiological states, and contraindications. This information is derived strictly from official government prescribing documents.

Official Eligibility and Non-Eligibility Status

Status Population Group
Use Allowed Adults (18+ years) and Children 2 years of age and above.
Use Not Recommended Children under 2 years of age, Pregnant women, and Breastfeeding women.
Contraindicated Patients with known Hypersensitivity to Diosmectite or its excipients, or patients with certain excipient-specific intolerances (e.g., Phenylketonuria if Aspartame is present).

Eligibility-Related Restrictions

Regulatory authorities advise that the medicine is not recommended for children under two years due to insufficient safety data concerning potential trace heavy metal absorption in this vulnerable age group. Furthermore, use is generally restricted in patients with severe pre-existing conditions, such as severe chronic constipation or intestinal obstruction, as use may aggravate these conditions. The status of 'not recommended' for pregnant and breastfeeding women is based on precautionary principles and a lack of sufficient data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Colidiaryl is classified as a non-systemic intestinal adsorbent, meaning it acts locally within the digestive tract and is not significantly absorbed into the bloodstream. As documented in official regulatory sources, this characteristic dictates the medicine's interaction profile, which focuses almost entirely on its physical capacity to adsorb co-administered substances.

Official Interaction Profile

Classification Statement Based on Official Regulatory Documents
Pharmacokinetic Basis Physical adsorption in the gastrointestinal lumen leading to reduced systemic exposure of the co-administered drug.
Interacting Substances Any other orally administered medicine is subject to potential interaction. Examples in official documentation include Macrolides, Tetracyclines, Digoxin, and Ranitidine.
Metabolic Interactions None documented, as the product is not absorbed and does not interact with systemic enzymes (e.g., CYP450) or transporters (e.g., P-gp).

Administration Requirements

Due to the adsorption effect, regulatory labels establish a mandatory condition for co-administration. Any other oral medicine must be administered with a timing separation of at least 2 to 3 hours before or after taking Colidiaryl. Simultaneously co-administering any other oral medicinal product with Colidiaryl is officially restricted to mitigate the risk of reduced absorption and efficacy of the co-administered drug. There are no explicitly documented interactions with food, alcohol, or herbal products that require specific restrictions.

Mechanism of Action

How Colidiaryl Works

The mechanism of Colidiaryl is entirely non-systemic, relying on the physical and chemical properties of its layered aluminomagnesium silicate structure to act directly within the intestinal lumen. The drug’s core function is dual: Adsorption and Physical Barrier Reinforcement.

Through adsorption, the particles exhibit a high surface affinity to bind and sequester intraluminal stressors, including excessive free water, bacterial enterotoxins, and irritating bile salts. This sequestration lessens the chemical stimuli contributing to epithelial hypersecretion and directly modifies the fluid dynamics and viscosity of the intraluminal contents.

Simultaneously, the drug adheres to and supplements the mucosal glycoproteins, providing a physical coating over the underlying intestinal epithelium. This reinforcement limits contact with intraluminal irritants and toxins, which in turn lowers the rate of fluid and electrolyte transit across the intestinal barrier. By reducing the activation of pathways associated with accelerated intestinal transit and fluid secretion, the mechanism contributes to a physiological environment characterized by reduced fluid discharge, without altering systemic pathways.

Dosage and Administration Information

Colidiaryl is administered exclusively via the oral route as a powder designed to form an aqueous suspension. The medicine is intended for short-term use, with treatment duration for acute episodes typically not exceeding seven days.

Standard Administration

Administration Parameter General Instruction
Dosing Schedule (Adults) The typical adult dose is 9 grams (3 sachets) per day. This amount may be increased up to 18 grams (6 sachets) daily at the start of treatment for acute cases.
Preparation The contents of the sachet must be thoroughly suspended in liquid, such as a half glass of water, and taken immediately after preparation.
Timing Doses should be taken in a divided manner (e.g., three times per day) and administered between meals.

Use in Specific Populations

For children over two years of age, a lower, age-appropriate dosing regimen is required. Administration in this pediatric group must be integrated with the use of an Oral Rehydration Solution (ORS). Due to the medicine's non-systemic action, no routine dosage adjustments are typically specified for older adults.

Procedural Constraints

A critical procedural constraint is the need to separate Colidiaryl from other oral medications. Because its adsorbent nature can affect the absorption of other drugs, a minimum interval of at least two hours is required between the intake of Colidiaryl and any other medicine taken by mouth. This procedural structure defines the standardized use of the drug.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Colidiaryl

The clinical evaluation of Colidiaryl (Diosmectite) has been the focus of research studies across several countries. The available evidence, detailed in official documents and peer-reviewed scientific literature, helps contextualize what has been observed so far in specific patient groups under controlled conditions.


Evidence Summary for Acute Diarrhea

Short-term Randomized Controlled Trials (RCTs) have been conducted to research how symptoms changed in patients using Colidiaryl. These studies were designed to monitor the medicine against a control, such as a placebo, over a defined, brief time interval. The outcomes monitored were outcomes reflecting daily functioning, specifically the changes in time to resolution and the overall duration of the acute episode.

Studies reported measurements of changes in time to resolution for the diarrheal episode in the observed populations. Research highlights changes measured during the study period, with some reports indicating that the medicine was observed in some studies to correlate with the time for the diarrheal episode to resolve. Studies report how symptoms evolved, with some data showing patterns related to changes in stool output and an earlier return to a regular stool form.

Despite these observations, research has found that evidence quality varies across studies, particularly due to differences in how trials were set up. Because acute diarrhea is a self-limiting condition, long-term effects are not fully established as the research ends shortly after recovery. Furthermore, official reviews have indicated that overall certainty remains low for some monitored outcomes.


Evidence Summary for Chronic and Functional Diarrhea

The research examining Colidiaryl's use in chronic conditions, such as Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D), is not as developed as for acute episodes. Research exploring this use typically involves intermediate-term controlled trials that applied in studies examining patient-reported experiences. The studies monitored outcomes related to physical discomfort, specifically tracking stool consistency and bowel movement frequency over defined time intervals.

Findings indicate a trend related to changes in daily bowel movement frequency and changes in stool form during the study period. Studies report how symptoms evolved, with patient-reported outcomes describing perceived discomfort also being monitored. However, the certainty of the findings in this area remains low.


Key Research Gaps and Uncertainties

Regulatory bodies and scientific reviews have highlighted that while Colidiaryl was observed in numerous studies, the evidence quality varies across studies. Findings were mixed when researchers examined some secondary outcomes, such as studies focusing on hospitalization rates in children with acute diarrhea. These limitations mean that while research provides insight into short-term changes and describes group patterns, comparative evidence for certain long-term or functional outcomes remains insufficient.

Frequently Asked Questions (FAQ)

Common questions about Colidiaryl (FAQ)

Q: Is Colidiaryl the same kind of medicine as other common treatments for this condition?

A: According to official classification, Colidiaryl is an intestinal adsorbent, meaning it works primarily by physically binding substances directly in the digestive tract. This mechanism is distinctly different from other common treatments for this condition, which may include motility inhibitors (acting to slow down bowel movements) or antispasmodics (acting to relieve cramping).


Q: Does Colidiaryl show up on drug screening tests?

A: Colidiaryl is defined in its product information as being non-systemic, meaning it acts locally in the digestive tract and is not significantly absorbed into the bloodstream. Because of this lack of systemic absorption, it is generally understood not to interfere with standard drug screening tests, as it does not enter the bloodstream significantly.


Q: Can older adults use Colidiaryl safely?

A: Regulatory documents indicate that the standard adult dosage is typically used for the elderly population, as routine dosage adjustments are not specified in the product information. However, the medicine is intended for short-term use only, and patients should refer to the product information or their healthcare provider for specific safety considerations.


Q: What does 'contraindication' mean for Colidiaryl?

A: In medicine, a contraindication refers to a situation where a particular treatment should not be used because the potential harm could outweigh the expected benefits. For Colidiaryl, official documents list contraindications such as a known hypersensitivity (allergic reaction) to its ingredients or certain severe, pre-existing digestive issues.


Q: Are there any known interactions between Colidiaryl and common supplements like melatonin?

A: Colidiaryl is an adsorbent, meaning its core action is to bind other substances within the gut. Due to this physical action, the product information indicates it can interfere with the absorption of any substance taken orally, including oral supplements. To minimize this risk, regulatory labels establish a mandatory timing separation of at least two hours between Colidiaryl and any other oral product.


Q: Does Colidiaryl come in different strengths or forms?

A: According to the official product information, Colidiaryl is approved and primarily provided as a powder for oral suspension in single-dose sachets. This sachet format is designed for easy mixing with liquid before ingestion.


Q: What is the difference between a common side effect and a serious adverse reaction to Colidiaryl?

A: Official documents classify adverse reactions based on their frequency (e.g., common, uncommon, or rare). Reactions in the 'rare' or 'not known' categories, such as a severe rash, hives (urticaria), or swelling (angioedema), are generally classified as rare or serious adverse reactions.


Q: Is it normal to feel tired when first starting Colidiaryl?

A: Tiredness or fatigue is not listed as an adverse reaction in the medicine's official safety profile. The product information generally reports that the medicine has no known influence on the nervous system, as its action is non-systemic.


Q: Does Colidiaryl affect or change my mood?

A: Official regulatory documents do not list changes in mood or psychiatric effects in the medicine's safety profile. The documented adverse reactions are primarily related to the gastrointestinal tract and the skin or immune system disorders.


Q: What should I do if I miss a scheduled time for Colidiaryl?

A: Official regulatory guidance addresses missed doses in the product patient information leaflet. The instructions provided are usually to take the dose when remembered, unless the next dose is due, in which case it is advised to skip the missed dose and continue the regular schedule. Consulting the patient information leaflet is important for specific guidance.


Q: Does taking Colidiaryl require any special monitoring by a doctor?

A: Due to its non-systemic action, no specific routine monitoring of systemic body functions is generally required by official guidelines. However, regulatory guidance highlights the importance of monitoring the overall fluid balance and rehydration status, especially when the medicine is used in children.


Q: Can Colidiaryl affect the results of lab tests?

A: Since the product is not absorbed, systemic interactions with liver enzymes or transporters are not documented in the product information. The primary documented risk is limited to the absorption of other orally taken substances, which could potentially affect the systemic exposure of those substances.


Q: Are there lifestyle changes suggested when using Colidiaryl?

A: Official safety warnings emphasize the necessity of adequate rehydration due to fluid and electrolyte loss from diarrhea. This generally involves consuming plenty of salty or sweet fluids while using the medicine.


Q: Is Colidiaryl known to cause dependency?

A: Official regulatory documents and substance abuse classifications do not list Colidiaryl as a medicine with a known potential for abuse or physical dependence. Its non-systemic, physical mechanism of action does not typically lead to dependency.


Q: Are there any specific warnings about driving or operating machinery while on Colidiaryl?

A: According to the official product information, the medicine is stated to have no, or negligible, influence on the ability to drive or operate heavy machinery, based on its safety profile and non-systemic action.


Q: Does the effectiveness of Colidiaryl wear off over time?

A: Official guidance advises against prolonged or chronic use, primarily because of safety constraints related to the risk of severe constipation or, rarely, the formation of a bezoar (a solid mass in the digestive tract). The restriction on long-term use is not due to a known loss of efficacy or tolerance.

How should Colidiaryl be stored and disposed of?

How to Store and Dispose of Colidiaryl?

Colidiaryl (Diosmectite, Powder for Oral Suspension) must be stored and handled strictly according to the official regulatory instructions to maintain its integrity.


Storage Requirements

The medicine should be stored at room temperature, typically below 25°C (77°F). Protection is required against moisture and light; therefore, the product must be kept in a dry place in its original sachet/packaging until use. The product must be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused Colidiaryl must be disposed of safely following local regulations. The preferred method is using a community drug take-back program. If this is unavailable, the product should be mixed with an undesirable substance, sealed in a bag, and placed in the household trash. It should not be flushed down the toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Colidiaryl found in:

A-Z Index: